Desipramine

Tricyclic antidepressant causing striking sustained increases in d-amphetamine brain concentration with potentiated cardiovascular effects.

Tricyclic antidepressant that causes striking and sustained increases in brain d-amphetamine concentration with potentiated cardiovascular effects.

Bupropion increased desipramine Cmax, AUC, and t1/2 by approximately 2-, 5-, and 2-fold, respectively; effect persisted for at least 7 days after last bupropion dose.

Methylphenidate may inhibit the metabolism of desipramine. Downward dose adjustments may be required and plasma drug concentration should be monitored.

Amphetamines enhance activity of desipramine causing striking and sustained effects.

Tricyclic antidepressant may enhance activity causing striking sustained increases in d-amphetamine concentration and potentiated cardiovascular effects. Monitor frequently and adjust therapy as needed.

Tricyclic antidepressant causing striking sustained increases in brain d-amphetamine concentration and potentiated cardiovascular effects.

Exposure increases 8-fold. Reduce desipramine dose and adjust based on clinical response.

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot be avoided.

CYP2D6 inhibitor that increases propafenone plasma levels, potentially causing cardiac arrhythmias and proarrhythmia risk.

CYP2D6 inhibitor that increases propafenone plasma levels, potentially leading to cardiac arrhythmias and proarrhythmia risk.

Steady state plasma concentrations of desipramine can increase by approximately 20% when coadministered with alprazolam up to 4 mg/day. Clinical significance unknown.

Steady state plasma concentrations increase by approximately 20% when administered concomitantly with alprazolam in doses up to 4 mg/day. Clinical significance unknown.

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases desipramine concentrations; consider dose reduction.

Bupropion inhibits CYP2D6 and can increase desipramine concentrations; consider dose reduction of desipramine.

CYP2D6 substrate antidepressant. Bupropion inhibits CYP2D6, increasing desipramine exposure. Dose reduction may be necessary.

CYP2D6 substrate. Bupropion inhibits CYP2D6 and can increase desipramine concentrations. Consider dose reduction of desipramine when used with bupropion.

CYP2D6 substrate; cinacalcet is a strong CYP2D6 inhibitor. Dose adjustment may be required for concomitant CYP2D6-metabolized medications.

Cinacalcet is a strong CYP2D6 inhibitor. Dose adjustments may be required for concomitant CYP2D6 substrate medications.

Desvenlafaxine increases desipramine levels. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Desvenlafaxine increases desipramine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Concomitant use increases exposure (Cmax and AUC). Reduce dose by up to one-half if co-administered with 400 mg desvenlafaxine.

Concomitant use may potentiate the cardiovascular effects of dopamine, including hypertension.

Coadministration resulted in 40% increase in desipramine Cmax. Desipramine is a CYP2D6 substrate metabolized by escitalopram.

Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma concentrations should be monitored.

Methylphenidate may inhibit metabolism of desipramine. Downward dosage adjustments may be required.

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Additive tachycardia, hypertension, and drowsiness reported with concurrent use.

Tricyclic antidepressant may cause dry mouth and diminished salivary secretions, making sublingual nitroglycerin dissolution difficult.

Paroxetine inhibits CYP2D6, increasing desipramine exposure. Decrease desipramine dosage if needed with concomitant paroxetine use.

Paroxetine inhibits CYP2D6, increasing exposure of desipramine. Dosage reduction may be needed.

Paroxetine inhibits CYP2D6 metabolism of desipramine, potentially increasing desipramine levels.

Terbinafine inhibits CYP450 2D6, resulting in 2-fold increase in Cmax and 5-fold increase in AUC of desipramine. Effects persist up to 4 weeks after discontinuation. Monitor and may require dose reduction.

Terbinafine inhibits CYP450 2D6 metabolism, resulting in 2-fold increase in Cmax and 5-fold increase in AUC. Effects persist for 4 weeks after discontinuation. Careful monitoring and dose reduction may be required.

Terbinafine inhibits CYP450 2D6, resulting in 2-fold increase in Cmax and 5-fold increase in AUC of desipramine. Effects persist for 4 weeks after discontinuation.

In vitro and in vivo studies showed tolcapone did not change desipramine pharmacokinetics or affect hemodynamic parameters when given with levodopa/carbidopa.